Michael Lytton Leaves Oxford Bioscience for Biogen
Michael Lytton has left Oxford Bioscience Partners, where he had been a general partner since 2001. He will become executive vice president of business and corporate development with Biogen Idec (Nasdaq: BIIB). All of his Oxford-related board seats have been reassigned.
26 February 2009•2 mins read
